Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1765-1772

  Emile, J F ^a,b   Brahimi, S ^a   Coindre, J M ^c   Bringuier, P P ^d   Monges, G ^e   Samb, P ^a   Doucet, L ^f   Hostein, I ^c   Landi, B ^g   Buisine, M P ^h   Neuville, A ^c,i   Bouche O ^j   Cervera, P ^k   Pretet, J L ^l   Tisserand, J ^a   Gauthier, A ^a   Le Cesne, A ^m   Sabourin, J C ⁿ   Scoazec, J Y ^d   Bonvalot, S ^m   Corless, C L ^o   Heinrich, M C ^o   Blay, J Y ^p   Aegerter, P ^a   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c INSTITUT BERGONIÉ   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j REIMS UNIVERSITY HOSPITAL   (France)

^k HÔPITAL SAINT ANTOINE   (France)

^l UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ ROUEN UNIVERSITY HOSPITAL   (France)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p CENTRE LÉON BÉRARD   (France)

more..

Author keywords

Epidemiology; Gastrointestinal tumor; Sarcoma; Tyrosine kinase receptor

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PROGNOSIS; EXON; FEMALE; FRANCE; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM; SMALL INTESTINE; STOMACH; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84867300058     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0074-y     Document Type: Article

References (30)

1. Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Apes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010;103:165-70.
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-25.
3. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731-41.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80.
5. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34.
6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10.
7. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-8.
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70-83.
9. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-905.
10. Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113-20.
11. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65.
12. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045-52.
13. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411-9.
14. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet. 2009;373:1097-104.
15. Emile JF, Lemoine A, Bienfait N, Terrier P, Azoulay D, Debuire B. Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors. Diagn Mol Pathol. 2002;11:107-12.
16. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133: 141-8.
17. Hostein I, Debiec-Rychter M, Olschwang S, et al. A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours. J Gastroenterol. 2011;46: 586-94.
18. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 2003;9: 3329-37.
19. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004;84:874-83.
20. Martín J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish group for sarcoma research (GEIS). J Clin Oncol. 2005;23:6190-8.
21. Bachet JB, Hostein I, Le Cesne A, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer. 2009; 101:7-11.
22. Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1, 640 patients. J Clin Oncol. 2010;28:1247-53.
23. Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET consensus panel of experts gastrointestinal stromal tumours: ESMO clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:98-102.
24. Corless CL, Ballman KV, Antonescu CD et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010; 28:15s (suppl; abstr 10006).
25. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M. Mutations in gastrointestinal stromal tumors: a population-based study from northern Norway. APMIS. 2007;115:289-98.
26. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53:245-66.
27. Wozniak A, Rutkowski P, Piskorz A, et al. Progonostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): polish clinical GIST registry experience. Ann Oncol. 2011 (in press).
28. Du CY, Shi YQ, Zhou Y, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol. 2008;98:175-8.
29. Braggio E, de Braggio DA, Small IA, et al. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Res. 2010;30:2407-14.
30. Braconi C, Bracci R, Bearzi I, et al. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol. 2008;19:706-10.